Investors
Investor relations
Latest news
Camurus and Lilly enter collaboration and license agreement for long-acting FluidCrystal® incretins
Camurus’ Board of Directors exercises authorization for repurchase of shares for the purpose of securing the company’s commitments under the Performance Share Plan 2025/2028
Resolutions at the annual general meeting 2025 in Camurus
Corporate presentation
-
16Jun
BIO International Convention 2025
Camurus will participate in this conference in Boston, MA, US, 16-19 June, 2025.
-
26Jun
ABG Sundal Collier Spotlight Conference
Camurus’ Chief Business Development Officer Fredrik Joabsson is presenting at this conference in Frankfurt, 26 June. The presentation can be seen by the conference participants. More information will follow closer to the event.
-
17Jul
Interim Report January-June 2025
The interim report January-June is published on 17 July 2025.
AGM 2025
Camurus’ Annual General Meeting 2025 was held on Tuesday, 27 May in Lund, Sweden.
Resolutions at the Annual General Meeting 2025 in Camurus
See documents for Annual General Meeting 2025
See more information on Camurus’ general meetings
See archive general meetings
Latest financial report
Camurus’ Interim Report January-March 2025
15 May 2025
CEO statement Q1 2025
“Productive first quarter with high profitability and pipeline progress“
ESG rankings
Camurus has an ambitious sustainability agenda with the aim of improving the company’s sustainability performance and contribution to the UN’s Sustainable Development Goals. Our performance and progress is regularly evaluated by independent third-party ESG ratings.
Nasdaq Transparency Partner
In 2023, Camurus became a Nasdaq ESG Transparency Partner. The certification demonstrates Camurus’ commitment to market transparency and raising environmental standards.
Investor contact
IPO and Prospectus
subscribe
Get the latest news from Camurus
Subscribe to receive latest news from Camurus driectly to your email.
